<DOC>
	<DOCNO>NCT00490711</DOCNO>
	<brief_summary>The purpose study evaluate efficacy paclitaxel carboplatin follow gemcitabine carboplatin therapy patient epithelial ovarian cancer .</brief_summary>
	<brief_title>Treatment Paclitaxel Plus Carboplatin Followed Gemcitabine Plus Carboplatin Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically verify epithelial ovarian cancer FIGO stage IIIIV Patients measurable disease . RECIST criterion GCIG modification use response progression assessment . Lesions serve measurable disease must longest diameter great equal 20 mm measure conventional technique great equal 10 mm spiral CT scan . Lesions measure physical examination must longest diameter great equal 20 mm . Ovarian tumor low malignant potential ( borderline tumor ) Nonepithelial ovarian mixed epithelial . non epithelial tumor ( e.g . mixed Mullerian tumor ) Time definitive surgery enrollment study great 6 week Patients receive previous chemotherapy radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>